|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 0.3040 SEK | -1.30% |
|
-2.88% | -17.84% |
| 10-23 | Biovica International Conditionally Raises SEK29 Million from Rights Issue | MT |
| 09-22 | Biovica International Wins Work Order for Early-stage Oncology Study | MT |
| Market Cap | 88.74M 8.81M 7.99M 7.39M 6.67M 12.56M 831M 13M 35.19M 444M 33.07M 32.37M 1.41B | P/E 2027 * |
-
| P/E 2028 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 88.74M 8.81M 7.99M 7.39M 6.67M 12.56M 831M 13M 35.19M 444M 33.07M 32.37M 1.41B | EV / Sales 2027 * |
3.52x | EV / Sales 2028 * | 1.99x |
| Free-Float |
56.85% | Yield 2027 * |
-
| Yield 2028 * | - |
Nasdaq StockholmSEK
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| BIOVIC B | Delayed | |
Deutsche Boerse AG
| 9II | Delayed | |
|
Boerse Muenchen
| 9II | Real-time | |
|
Börse Stuttgart
| 9II | Delayed |
Last Transcript: Biovica International AB
| 1 day | -1.30% | ||
| 1 week | -2.88% | ||
| Current month | -15.32% | ||
| 1 month | +2.70% | ||
| 3 months | -42.64% | ||
| 6 months | -9.52% | ||
| Current year | -17.84% |
| 1 week | 0.3 |  | 0.35 |
| 1 month | 0.29 | | 0.38 |
| Current year | 0.27 | | 0.58 |
| 1 year | 0.27 | | 0.6 |
| 3 years | 0.27 | | 3.4 |
| 5 years | 0.27 | | 49.95 |
| 10 years | 0.27 | | 69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Theis Kipling
CEO | Chief Executive Officer | 44 | 2026-04-30 |
Anders Morén
DFI | Director of Finance/CFO | 61 | 2022-12-31 |
Hanna Ritzen
COO | Chief Operating Officer | 47 | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Anders Rylander
BRD | Director/Board Member | 56 | 2009-12-31 |
Maria Holmlund
BRD | Director/Board Member | 70 | 2015-12-31 |
| Director/Board Member | 60 | 2012-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/11/25 | Buy | Director | 1,871,925 | 2.2265% | ||
| 12/20/23 | Buy | Executive/Senior Manager | 1,700 | 0.0040% | ||
| 8/24/22 | Others | Director | 46,700 | 0.2135% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.30% | -2.88% | -46.85% | -88.31% | 8.81M | |
| -2.69% | -0.48% | +51.67% | +69.09% | 66.33B | |
| -0.92% | +7.67% | +14.26% | +90.92% | 60.62B | |
| 0.00% | +0.39% | +20.52% | +98.45% | 55.5B | |
| +0.14% | +2.35% | +13.08% | +109.47% | 47.58B | |
| -2.21% | -2.47% | +18.60% | +36.89% | 43.69B | |
| -2.30% | -10.40% | +167.61% | +776.79% | 37.27B | |
| +2.15% | +1.42% | +15.17% | +56.49% | 36.57B | |
| -2.32% | -2.24% | +75.52% | +52.70% | 32.22B | |
| +2.62% | +5.90% | -36.55% | +406.95% | 26.58B | |
| Average | -0.68% | -0.24% | +29.30% | +160.94% | 41B | |
| Weighted average by Cap. | -0.83% | +0.20% | +37.23% | +162.19% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 25.2M 2.5M 2.27M 2.1M 1.89M 3.57M 236M 3.69M 9.99M 126M 9.39M 9.19M 400M | 44.6M 4.43M 4.01M 3.71M 3.35M 6.31M 418M 6.54M 17.68M 223M 16.62M 16.27M 708M |
| Net income | -58M -5.76M -5.22M -4.83M -4.36M -8.21M -543M -8.5M -23M -290M -21.62M -21.16M -921M | -33.9M -3.37M -3.05M -2.82M -2.55M -4.8M -317M -4.97M -13.44M -170M -12.63M -12.37M -538M |
| Net Debt | - | - |
Employees
24
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-13 | SEK 0.3040 | -1.30% | 102,140 |
| 26-11-12 | SEK 0.3080 | -4.94% | 403,654 |
| 26-11-11 | SEK 0.3240 | +4.52% | 319,338 |
| 26-11-10 | SEK 0.3100 | -2.82% | 381,540 |
| 26-11-09 | SEK 0.3190 | +1.92% | 355,952 |
- Stock Market
- Stocks
- BIOVIC B Stock
Select your edition
All financial news and data tailored to specific country editions
